Seth J. Karp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seth J. Karp has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Alexander H. K. Kroemer
Departments of 1Surgery and 3Medicine, Beth Israel Deaconess Medical Center, 2Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts
1 shared publicationAmy Evenson
Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA
1 shared publicationBeth Israel
Deaconess Medical Center Boston Mass
1 shared publication- Caroline Evelyn Bass
Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo Buffalo, NY, USA
1 shared publication Christin P. Rogers
The Transplant Center Beth Israel Deaconess Medical Center (BIDMC) Harvard Medical School Boston MA USA
1 shared publicationChunyan Ma
Departments of 1Surgery and 3Medicine, Beth Israel Deaconess Medical Center, 2Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts
1 shared publication
Latest Publications
- 1 May 2012
- Published by Wiley in Clinical Transplantation
- Vol. 26 (3) , E269-E276
Liver transplant center risk tolerance
Recent changes in Center for Medicare & Medicaid Services (CMS) condition for participation, using benchmark volume/outcomes requirements for certification, have been implemented. Consequently, the ability of a transplant center to assess its risk tolerance is important in successful management. An analysis of SRTR data was performed to determine donor/recipient risk factors for graft loss or patient death in the first year. Each transplant performed was then assigned a prospective relative risk (RR) of failure. Using a Monte-Carlo simulation, transplants were selected at random that met the centers’ acceptable risk tolerance. Transplant center volume was fixed and its risk tolerance was adjusted to determine the impact on outcomes. The model was run 1000 times on centers with varying volume. The modeling demonstrates that centers with smaller annual volumes must use a more risk taking strategy than larger volume centers to avoid being flagged for CMS volume requirements. The modeling also demonstrates optimal risk taking strategies for centers based upon volume to minimize the probability of being flagged for not meeting volume or outcomes benchmarks. Small volume centers must perform higher risk transplants to meet current CMS requirements and are at risk for adverse action secondary to chance alone.
- 1 May 2012
- Published by Wiley in Clinical Transplantation
- Vol. 26 (3) , E269-E276
Liver transplant center risk tolerance
Recent changes in Center for Medicare & Medicaid Services (CMS) condition for participation, using benchmark volume/outcomes requirements for certification, have been implemented. Consequently, the ability of a transplant center to assess its risk tolerance is important in successful management. An analysis of SRTR data was performed to determine donor/recipient risk factors for graft loss or patient death in the first year. Each transplant performed was then assigned a prospective relative risk (RR) of failure. Using a Monte-Carlo simulation, transplants were selected at random that met the centers’ acceptable risk tolerance. Transplant center volume was fixed and its risk tolerance was adjusted to determine the impact on outcomes. The model was run 1000 times on centers with varying volume. The modeling demonstrates that centers with smaller annual volumes must use a more risk taking strategy than larger volume centers to avoid being flagged for CMS volume requirements. The modeling also demonstrates optimal risk taking strategies for centers based upon volume to minimize the probability of being flagged for not meeting volume or outcomes benchmarks. Small volume centers must perform higher risk transplants to meet current CMS requirements and are at risk for adverse action secondary to chance alone.
- 1 June 2010
- Published by Springer Nature in Science-Business eXchange
- Vol. 3 (24) , 729
Transducer of ERBB2 1 (TOB1)
- 1 June 2010
- Published by Springer Nature in Science-Business eXchange
- Vol. 3 (24) , 729
Transducer of ERBB2 1 (TOB1)
- Open Access
- 1 September 2009
- Published by Elsevier in American Journal of Transplantation
- Vol. 9 (9) , 1973-1980
Clinical Implications of Advances in the Basic Science of Liver Repair and Regeneration
- 1 September 2009
- Published by Elsevier in American Journal of Transplantation
- Vol. 9 (9) , 1973-1980
Open AccessClinical Implications of Advances in the Basic Science of Liver Repair and Regeneration
- 1 August 2008
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 295 (2) , G412-G419
Optimized adeno-associated virus 8 produces hepatocyte-specific Cre-mediated recombination without toxicity or affecting liver regeneration
Engineering viral vectors to produce liver-specific protein expression may help advance understanding of hepatic regeneration and disease states. In addition to introducing genes of interest to the liver, these vectors can be adapted for gene deletion when designed to express Cre recombinase. The ability to use this system requires high, liver-restricted expression, low toxicity, and no effect on the process of interest. We developed an adeno-associated virus 8 (AAV8) with a codon-optimized Cre recombinase under a hepatocyte-specific major urinary protein (MUP) promoter (MUP-iCre-AAV8) that fulfills these requirements. A single intravenous injection of ROSA26R reporter mice, which express lacZ after Cre-mediated recombination, demonstrated homogeneous β-galactosidase expression limited to hepatocytes after only 7 days. Cre protein expression remained strong for at least 31 days. Serum liver function tests and histology demonstrated minimal liver toxicity. The presence of MUP-iCre-AAV8 did not affect hepatocyte proliferation after partial hepatectomy as measured by Ki67 staining. Conclusion: AAV8 with the MUP promoter, by virtue of its lack of hepatic toxicity or effect on liver regeneration, may be an efficient alternative to complex transgenic methodologies for studies of the mouse liver.
- 1 August 2008
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 295 (2) , G412-G419
Optimized adeno-associated virus 8 produces hepatocyte-specific Cre-mediated recombination without toxicity or affecting liver regeneration
Engineering viral vectors to produce liver-specific protein expression may help advance understanding of hepatic regeneration and disease states. In addition to introducing genes of interest to the liver, these vectors can be adapted for gene deletion when designed to express Cre recombinase. The ability to use this system requires high, liver-restricted expression, low toxicity, and no effect on the process of interest. We developed an adeno-associated virus 8 (AAV8) with a codon-optimized Cre recombinase under a hepatocyte-specific major urinary protein (MUP) promoter (MUP-iCre-AAV8) that fulfills these requirements. A single intravenous injection of ROSA26R reporter mice, which express lacZ after Cre-mediated recombination, demonstrated homogeneous β-galactosidase expression limited to hepatocytes after only 7 days. Cre protein expression remained strong for at least 31 days. Serum liver function tests and histology demonstrated minimal liver toxicity. The presence of MUP-iCre-AAV8 did not affect hepatocyte proliferation after partial hepatectomy as measured by Ki67 staining. Conclusion: AAV8 with the MUP promoter, by virtue of its lack of hepatic toxicity or effect on liver regeneration, may be an efficient alternative to complex transgenic methodologies for studies of the mouse liver.